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Objective. To describe TB/HIV clinic outcomes in a rural, Ministry of Health hospital. Design. Retrospective, secondary analyses.
Descriptive statistics and logistic regression analyses evaluated baseline characteristics and outcomes. Results. Of 1,911 patients,
89.8% were adults aged 32.0 (±12.6) years with baseline CD4 = 243.3( ±271.0), 18.2% <50cells/mm3. Pulmonary (84.8%,
(32.2% smear positive)) exceeded extrapulmonary TB (15.2%). Over 5 years, treatment success rose from 40.0% to 74.6%, lost
to follow-up dropped from 36.0% to 12.5%, and deaths fell from 20.0% to 5.4%. For patients starting ART after TB treatment,
those with CD4 ≥50cells/mm3 were twice as likely to achieve treatment success (OR = 2.0, 95% CI=1.3–3.1) compared to those
with CD4 <50cells/mm3. Patients initiating ART at/after 2 months were twice as likely to achieve treatment success (OR = 2.0,
95% CI=1.3–3.3). Yearly, odds of treatment success improved by 20% (OR = 1.2, 95% CI=1.0–1.5). Conclusions. An integrated
TB/HIV clinic with acceptable outcomes is a feasible goal in resource-limited settings.
1.Introduction
Tuberculosis (TB) remains the leading cause of death among
persons living with HIV/AIDS with nearly 25% of HIV
mortality attributable to TB and 380,000 deaths in 2009
related to HIV-associated TB [1]. In 2009, there were an
estimated 1.1 million HIV-positive TB patients globally
with nearly 80% living in sub-Saharan Africa [1]. While
guidelines [2–5] and peer-reviewed journals [6–12]c a l lf o r
integrated TB/HIV services and clinical trials demonstrate
early antiretroviral therapy (ART) in patients with TB/HIV
coinfection result in better outcomes [13–16], experience
from ﬁeld implementation of TB/HIV integration is now
critical.
The Kericho District Hospital (KDH), a Ministry of
Health public hospital in rural Kenya, fully integrated HIV
services into their TB clinic in 2005 quickly following the
development of their HIV clinic services. Integration was
deemed necessary for a variety of reasons: (1) treatment
of one patient with two diseases (TB/HIV) seemed more
practical in a single location; (2) both patients and clinicians
preferred a combined TB/HIV care delivery system [10]; (3)
the belief that treatment outcomes could be maximized by
developing a cadre of health care providers capable of pro-
viding both TB and HIV treatments; (4) planned increases in
HIV testing within the TB clinic would result in identifying
large numbers of HIV-infected persons that could over-
whelm a burdened HIV clinic (who would already received
treatment in the TB clinic); (5) rudimentary infection
control in the HIV clinic could be strengthened by caring for
all TB/HIV suspects in the TB clinic rather than comingling
in the HIV clinic.
T h eo b j e c t i v e so ft h i ss t u d yw e r et od e s c r i b ec h a r a c t e r -
istics of patients enrolled in the TB/HIV clinic, consider2 AIDS Research and Treatment
changes in treatment success over time, evaluate TB treat-
ment outcomes given baseline CD4+ T-cell counts and
timing of ART, and explore the relationship between baseline
characteristics and treatment success.
2.MaterialsandMethods
2.1. Study Design. We conducted a retrospective, secondary
analysis of KDH clinic electronic medical records.
2.2. Study Setting. K D Hi sl o c a t e di nK e r i c h oa m o n gt h e
tea ﬁelds and plantations of Kenya’s southern Rift Valley
Province 260 kilometers northwest of Nairobi. As a Ministry
of Health (MoH) facility under the Ministry of Medical
Services, KDH provides services to a rural, largely uninsured
population, representative of the national statistic indicating
that 46% of the population lives below the poverty line [17].
In 2010, approximately 12,000 patients received inpatient
and approximately 160,000 patients received outpatient ser-
vices[18].BothHIVandTBservicesareprovidedbyfunding
from the Government of Kenya/MoH [19, 20] and through
donor programs, principally the President’s Emergency Plan
for AIDS Relief (PEPFAR) [21]. TB and HIV care services
including HIV Counseling and Testing and Prevention of
Mother- to- Child Transmission (PMTCT) operate in part-
nership with the Kenya Medical Research Institute/Walter
Reed Project (KEMRI/WRP) HIV Program. The KEMRI/
WRP partnership is part of the US Military HIV Research
Program (MHRP), an international HIV vaccine research
program under the Walter Reed Army Institute of Research
(WRAIR) [22, 23].
The MoH in collaboration with KEMRI/WRP under the
PEPFAR program supports HIV care, prevention, and treat-
ment services in the southern Rift Valley Province of Kenya
(population of approximately 2.5 million). Beginning with
4 initial treatment sites (including KDH) in 2004, program
coverage now includes 11 district level, primary treat-
ment facilities, 10 subdistrict hospitals, 75 dispensaries/rural
health centers, and 403 PMTCT sites. Expansion has been
based upon a network model focusing upon decentralization
in an eﬀort to bring services closer to communities and
decongest primary treatment centers. After the initial KDH
TB/HIV clinic opened in 2005, expansion of integrated TB/
HIV services began in 2007 and currently includes 8 TB/HIV
integrated clinics (Figure 1).
In late 2005, KDH opened the integrated TB/HIV
clinic using current MoH TB and HIV guidelines as well
as expert consultation (EJC). Operational components of
the integrated TB/HIV clinic included (1) HIV Diagnostic
Testing and Counseling (DTC) for patients and family
members presenting to the TB clinic where >90% annual
patient acceptance rate was achieved [18]; (2) use of “cough
monitors” (trained lay individuals) to maximize sputum
collectioninaneﬀorttoimprovecaseﬁndingandcategoriza-
tion of TB disease, (3) referral to the TB clinic of all patients
diagnosed with TB in the HIV clinic at KDH as well as local
subdistrict hospitals and dispensaries/rural health centers;
and, (4) treatment for HIV including ART in the TB clinic
with patient referral for continued care to the HIV clinic on
completion of TB therapy.
Trimethoprim/sulfamethoxazole prophylaxis is routinely
provided to all HIV-infected patients. Patients receive
multivitamins for nutritional supplementation as well as
pyridoxine while on isoniazid for prevention of peripheral
neuropathy. TB, HIV, and TB/HIV coinfection preven-
tion, diagnoses, and treatments evolve based upon current
national guidelines and are conducted with support from
and under the auspices of Division of Leprosy, Tuberculosis,
and Lung Diseases (DLTLD) and National AIDS and STI
Control Programme (NASCOP) [3, 24–29]. The TB/HIV
clinic is staﬀed primarily by clinical oﬃcers and nurses and
is supplemented by DTC staﬀ, cough monitors, and a nutri-
tionist. Medical oﬃcers and consultants (mostly Internists)
see patients 1-2 days a week or as needed.
TB intensive phase treatment consists of isoniazid,
rifampin, pyrazinamide, and ethambutol for 2 months
in a ﬁxed dose combination with followup weekly. TB
continuation phase treatment initially consisted of isoniazid
and ethambutol for 6 months in a ﬁxed dose combination
until 2009 when country guidelines changed the regimen to
isoniazid and rifampin for 4 months in a ﬁxed dose combi-
nation. Continuation phase visits were scheduled monthly.
First-line ART prescribed in the TB clinic was in accordance
with national guidelines and consisted initially of stavudine
or zidovudine, lamivudine, and efavirenz until 2010 when
tenofovir became available and stavudine was removed
from ﬁrst-line recommendations. TB and ART medications
were dispensed on the same schedule. No drug stockouts
of TB medications or ART were experienced during the
study period. However, postelection violence occurred in
Kenya beginning December 29, 2007 and resulted in the
displacement of up to 600,000 individuals and over 1,000
deaths. The region of violence included Kericho and resulted
in displacement of both patients and staﬀ during the study
period.
2.3. Data Collection and Variables. Data were collected
from the KDH TB/HIV and HIV clinic electronic medical
records systems. These KDH MS Access databases include
clinical information from both clinic encounter forms and
laboratory results. Data were extracted from both the
TB/HIV and HIV clinic databases and merged by patient
clinic number to allow evaluation of KDH HIV clinic
followup. A ﬁnal password protected, anonymous database
was created for all retrospective, secondary analyses and
stored in the KEMRI/WRP Clinical Research Center secured,
double-locked Information Department. Basic demographic
and medical information extracted included age, gender,
baseline CD4+ T-cell count, TB type, treatment and referral
categories, and TB treatment outcomes.
2.4. Statistical Analysis. Descriptive analyses including
paired t-tests and chi-square or Fisher’s exact tests where
appropriatewereusedforbaselinecharacteristicsandfollow-
up outcomes. Unadjusted and adjusted multivariable logistic
regression analyses were used to examine the relationship
between baseline characteristics, clinic year, and outcomes.AIDS Research and Treatment 3
Figure 1: Kericho District Hospital Integrated TB/HIV Clinic (est. 2005) and subsequent roll-out of seven regional integrated TB/HIV
clinics (est. 2007–2009). Notes: DH: District Hospital, MH: Mission/Faith Based Hospital, SDH: Sub-District Hospital.
Data compilation and statistical analyses were completed
using Microsoft Excel and PC SAS (SAS Institute, Carey,
NC). Further details are outlined in protocol RV215 [30].
2.5. Ethics Approval. This study was reviewed and approved
by the Kenya Medical Research Institute, Lifespan, and Wal-
ter Reed Army Institute of Research respective Institutional
Review Boards and/or Ethics Review Committees.
3. Results
3.1. Baseline Characteristics. Between 2005 and 2010, 1,911
TB/HIV coinfected patients were registered in the TB/HIV
clinic: 1,716 adult (52.6% female) and 195 pediatric (58.5%
female) (Table 1). Of the adults, 42.8% were in care in
the HIV Clinic at the time of their TB diagnosis, resulting
in enrollment at the combined clinic. Most adults (51.2%)
had their TB diagnosis at the TB clinic and were diagnosed
with HIV coinfection by HIV rapid testing in the TB clinic.
The remaining adults were referred to the integrated clinic
from outside facilities. For pediatric patients, this ratio was
reversed with 59.0% cared for in the HIV clinic prior to TB
diagnosis and 36.9% having TB diagnosed initially followed
by HIV testing in the TB clinic.
Most adults (84.8%) presented with pulmonary TB
(34.9% smear positive) and advanced HIV disease (mean
CD4+ T-cell count = 216.4 ± 206.8cells/mm3, CD4+ T-cell
count <50cells/mm3 = 18.4%). Although pediatric patients
presented with similar frequencies of pulmonary TB, far
fewer were smear positive (8.7%) but their HIV disease
was advanced (CD4+ T-cell count <50cells/mm3 = 16.2%).
Nearly all received chest X-rays (93.0% and 95.9%, resp.),
contributing to diagnosis in smear negative cases.
Among the 1,911 enrolled in the TB/HIV clinic, 684
(35.8%) initiated ART through care in the integrated clinic
while receiving TB therapy. Few patients (186 (9.7%)) were
already treated with ART at the time of TB diagnosis and had
care transferred to the integrated clinic. Most patients (1,041
(54.5%)) with higher CD4+ T-cell counts received ART in
the HIV clinic after completion of TB therapy, reﬂecting
treatment approaches prior to more recent guidelines.
3.2. TB Treatment Outcomes. Overall 5-year treatment suc-
cess (cure or completion of therapy) frequencies were 74.7%
in children but only 56.8% in adults (Table 2). Proportions
lost to followup were high: 14.1% in children and 20.7%
in adults. Frequencies of death (5.9% and 8.2%, resp.)
were low, although these likely reﬂect an underestimate if
the much larger proportions of lost to followup (14.1%
in pediatrics and 20.7% in adults) included patients who
died. For adult and pediatric patients over the 5-year period,
treatment success rose from 40.0% in 2005 to 74.6% in
2010 (Figure 2). A notable, temporary decrease in treatment
success occurred in 2007-2008. This reversal may reﬂect the
societal unrest during the postelection violence that resulted
in displacement of both patients and staﬀ. Also during the
5-year period, proportions lost to followup (36.0% year-1 to
12.5%year-5)andhavingdied(20.0%year-1to5.4%year-5)
also improved.
Inthe684patientswhostartedARTwhileonTBtherapy,
ART was initiated on average 74.0 (±93.1) days following
TB treatment initiation. Review of TB treatment outcomes
stratiﬁed by baseline CD4+ T-cell count distribution reveals
that those patients with a CD4 count of <50cells/mm3 had
the highest proportion of death (10.7%) and accounted for
over half of the deaths in the entire cohort (Table 3(a)).4 AIDS Research and Treatment
Table 1: Characteristics of TB/HIV coinfected patients upon enrollment in the Kericho District Hospital Integrated TB/HIV Clinic1.
Pediatric (≤15 years old)
n = 195 (10.2%)
Adult (>15 years old)
n = 1,716 (89.8%) Overall n = 1,911
Age (yrs)2 6.6 (±4.0) 34.9 (±9.7) 32.0 (±12.6)
6.0 [1–15] 34.0 [16–80] 32.0 [1–80]
Female (%) 58.5 52.6 53.2
CD4+ T-cell count
(cells/mm3)2
551.1 (±568.9) 216.4 (±206.8) 243.3 (±271.0)
398.5 [2-3,151] 153.0 [1-1,609] 165.0 [1–3,151]
CD4 distributions (%)2
<50 (cells/mm3) 16.2 18.4 18.2
50–99 (cells/mm3) 5.4 16.3 15.4
100–199 (cells/mm3) 7.7 24.3 22.9
200-349 (cells/mm3) 16.2 21.3 20.8
≥350 (cells/mm3) 54.6 19.8 22.6
TB type (%)
(I) Pulmonary 84.1 84.8 84.8
(1.a) Smear positive2 8.7 34.9 32.2
(1.b) Chest X-ray done 95.9 93.0 93.3
(II) Extrapulmonary 15.9 15.2 15.2
Treatment category3
New 93.3 89.0 89.5
Transfer in 1.0 3.7 3.4
Returned defaulter 0.5 2.9 2.7
Relapse 5.1 4.4 4.4
Referral origin2
HIV clinic 59.0 42.8 44.5
TB clinic 36.9 51.2 49.8
Private 1.5 3.7 3.5
Other 2.5 2.2 2.2
1Data presented as proportion (%) or mean (±SD) and median [range]. Missing data: CD4 = 15.4%; TB type, treatment category, referral, and family testing
<1.0%.
2P<0.05.
3P<0.001.
Table 2: TB treatment outcomes of TB/HIV coinfected patients enrolled in the Kericho District Hospital Integrated TB/HIV Clinic.
Pediatric (<15 years old) n = 195 Adults (>15 years old) n = 1716
TB treatment outcome
Cure 7 (4.1) 243 (16.0)
Treatment complete 120 (70.6) 621 (40.8)
Transferred out 9 (5.3) 217 (14.3)
Lost to Followup 24 (14.1) 315 (20.7)
Died 10 (5.9) 125 (8.2)
Treatment success 127 (74.7) 864 (56.8)
Notes:
(1) Data presented as number (percentage). Missing data for TB treatment outcome = 12.9% for pediatric and 11.3% for adult patients.
(2) Treatment success deﬁned as cure or treatment complete.
Treatment success frequencies improved in relationship to
increasing baseline CD4+ T-cell count. Lost-to-followup
frequencies were high (10.9–12.8%) in all CD4+ T-cell
strata less than 200cells/mm3. Lost-to-followup frequencies
dropped by half in patients with CD4+ T-cell counts above
200cells/mm3. Similarly in review of outcome data by time
of ART initiation, poor outcomes as deﬁned by either death
or lost to followup were highest in those who started ART
earliest following TB treatment initiation, likely reﬂecting
their advanced HIV disease (Table 3(b)). For patients whoAIDS Research and Treatment 5
Table 3: (a) TB treatment outcomes according to baseline CD4 category in patients initiating ART following TB treatment in the Kericho
District Hospital Integrated TB/HIV clinic (n = 684). (b) TB treatment outcomes according to time of ART initiation in patients in the
Kericho District Hospital Integrated TB/HIV Clinic (n = 870).
(a)
CD4 distributions (cells/mm3) TB treatment outcome Row totals
Treatment success Transferred out Lost to followup Died
<50 116 (66.3) 18 (10.3) 22 (12.8) 19 (10.7) 175 (28.6)
50–99 101 (68.7) 21 (14.3) 16 (10.9) 9 (6.1) 147 (24.0)
100–199 163 (77.3) 18 (8.5) 27 (12.8) 3 (1.4) 211 (34.5)
200–349 53 (86.9) 4 (6.6) 3 (4.9) 1 (3.1) 61 (10.0)
≥350 16 (88.9) 1 (5.6) 1 (5.6) 0 (0) 18 (2.9)
Notes:
(1) Data presented as number (percentage for row total). Data missing: 10.5% for combination of CD4 distributions and TB treatment outcome.
(2) Treatment Success deﬁned as cure or treatment complete.
(b)
Time of ART Tb Treatment Outcome Row totals
Treatment success Transferred out Lost to followup Died
ART Prior to TB Treatment 122 (75.3) 12 (7.4) 14 (8.6) 14 (8.6) 162 (20.5)
ART Following TB Treatment
<2 weeks 39 (65.0) 5 (8.3) 10 (16.7) 6 (10.0) 60 (7.6)
2w e e k s – <2 months 227 (66.8) 50 (14.7) 45 (13.2) 18 (5.3) 340 (43.0)
2–6 months 143 (81.7) 7 (4.0) 15 (8.6) 10 (5.7) 175 (22.2)
>6 months 49 (92.5) 1 (1.6) 2 (3.8) 1 (1.9) 53 (6.7)
Notes:
(1) Data presented as number (percentage of row total). Data missing: 10.1% for combination of time of ART and TB treatment outcome.
(2) Treatment success deﬁned as cure or treatment complete.
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Figure 2: Overall treatment success by year in the Kericho District
HospitalTB/HIVClinic.Note:treatmentsuccessdeﬁnedaspropor-
tion with cure or treatment complete.
survived the ﬁrst two months of TB treatment to initiate
ART, treatment success rose to 81.7–92.5%, clearly above the
WHO target guidelines.
3.3. Baseline Characteristics, Clinic Year, and Treatment
Success. Exploratory analyses were conducted in an eﬀort to
understand the relationship between baseline characteristics
(age, gender, CD4+ T-cell count, and time until ART
initiation), clinic year, and treatment success (cure or treat-
ment complete versus death or loss to followup) (Table 4).
Individually, CD4+ T-cell count, time until ART initiation,
and clinic year were predictive of treatment success. TB/HIV
coinfected patients with CD4+ T-cell counts greater than or
equalt o50or200c ells/mm 3 w er e2.0t o3.5timesmor elik ely
to achieve treatment success (OR = 2.0 95% CI = 1.3–3.1 and
OR = 3.5, 95% CI 1.4–8.9, resp.) compared to patients whose
CD4+ T-cell counts were less than 50 or 200cells/mm3.
Similarly, patients initiating ART after 2 weeks or 2 months
were twice as likely to achieve treatment success (OR = 1.9,
95% CI = 1.0–3.5 and OR = 2.0, 95% CI = 1.3–3.3, resp.).
Yearly, the odds of participants having treatment success
improved by approximately 20% (OR = 1.2, 95% CI = 1.0–
1.5). In multivariate analysis, CD4 category, time until ART,
and clinic year remained signiﬁcant.
4. Discussion
Our experience demonstrates that integrated TB/HIV care
is feasible at a rural, public MoH hospital in Kenya. Our
integrated clinic, staﬀed primarily by clinical oﬃcers and
nurses with backup assistance by medical oﬃcers and
consultants, successfully administered TB and ART care with
acceptable TB treatment success frequencies that improved
over time. Overall mortality was low in the TB/HIV clinic for
both adult and pediatric patients. However, lost-to-followup
frequencieswerehighandoccurredearlyincare,particularly
in those presenting with advanced HIV. Many of these
patients lost to followup likely account for additional deaths.
Our data suggest that achieving Kenyan national TB targets6 AIDS Research and Treatment
Table 4: Relationship of treatment success in patients starting antiretroviral therapy after TB treatment in the Kericho District Hospital
TB/HIV Clinic (n = 684).
Odds of treatment success (cure or treatment complete) versus death or loss to followup
Characteristic
Univariate model Multivariate model1
OR 95% CI P OR 95% CI P
Age
Adult 0.4 0.1–1.5 0.2 — — —
Pediatric reference
Gender
Male 0.7 0.5–1.1 0.09 — — —
Female reference
CD4 Category
≥50cells/mm3 2.0 1.3–3.1 <0.01 1.7 1.0–2.7 0.04
<50cells/mm3 reference reference
CD4 Category
≥200cells/mm3 3.5 1.4–8.9 <0.01 2.4 0.9–6.3 0.09
<200cells/mm3 reference reference
Time Until ART
≥2 weeks 1.9 1.0–3.5 0.05 1.3 0.6–2.7 0.5
<2 weeks reference reference
Time Until ART
≥2 months 2.0 1.3–3.3 <0.01 1.8 1.1–3.0 0.03
<2 months reference reference
Clinic Year
Year (2–5, 1 year increment) 1.2 1.0–1.5 0.02 1.3 1.1–1.6 <0.01
previous year reference reference
Notes:
OR: odds ratio, CI: conﬁdence interval.
1Adjusted for CD4 categories, time until ART categories, and clinic year.
of 85% cure and 90% treatment completion rates regardless
of HIV status can only be achieved if loss to followup is
aggressively and promptly addressed.
Proportions of patients lost to followup improved from
36% in year 1 to 12.5% in year 5. Interventions employed by
the TB/HIV clinic felt to have been beneﬁcial in improving
loss to followup rates include (1) early and continuous
patient education regarding both TB and HIV therapies by
both clinic staﬀ as well as persons living with HIV/AIDS;
(2) eﬀort to rapidly identify patients who miss appointments
with the use of “tracers” who use village maps obtained
with patient permission upon clinic enrollment; (3) use of
treatment partners and directly observed therapy (DOT).
However, additional qualitative research is required to
understand why patients disengage with health care, and
innovative solutions are urgently required.
In parallel with the declining loss to follow-up, treatment
successroseanddeathratesfellovertime.Onemayspeculate
that these improvements reﬂect an increased experience
and competency in managing well-described complications
of TB/HIV treatments including immune reconstitution
syndrome, drug interactions, and comorbidities in addition
to increased attention to adherence and earlier treatment for
patients with lower CD4+ T-cell counts as newer guidelines
appeared[4,5].GiventheKerichoDistrictHospitalservedas
a regional hospital and was the ﬁrst to provide comprehen-
sive HIV services in the region, outcomes observed may also
r e ﬂ e c tar e f e r r a lb i a s ,w h i c hb e c a m el e s sp r o n o u n c e do v e r
time as other facilities became available and decentralization
of services occurred.
We found baseline CD4+ T-cell count highly associated
with treatment success. Patients with lower CD4 counts
most in need of ART were less likely to achieve treatment
successcomparedtothosewithhigherCD4counts,although
treatmentsuccessimprovedovertime.Theseﬁndingsunder-
score challenges in implementing early ART in patients with
advanced immunosuppression and achieving results seen
in recent clinical trials [14–16]. Challenges of introducing
ART early during TB intensive phase treatment in patients
withadvancedimmunosuppressioninresource-limitedareas
are profound, and diﬀerences in outcomes observed in
clinical trial versus clinical care settings well described in
the resource-rich settings are likely magniﬁed in resource-
constrained settings [31]. Barriers to early ART are both
medical (e.g., pill burden, adherence, toxicities, immune
reconstitution syndrome, and comorbidities) and logistical
(e.g., frequent appointments requiring travel time and costs,
time away from family and work). Clinical trials are betterAIDS Research and Treatment 7
resourced to address these medical and logistical issues, not
thecaseinresource-constrainedhealthcaresystems.Innova-
tion will be critical in solving these challenges.
Hospitalization, while theoretically practical for pro-
foundly immunosuppressed patients who are initiating both
TB treatment and ART, may often not be possible or ideal.
The lack of strong infection control programs within hos-
pitals in sub-Saharan Africa resulting in nosocomial TB
transmission raises a cautionary note [32]. The risk of
hospitalization with poor infection control is particularly
problematic in areas such as Kenya where TB drug suscep-
tibility data is lacking. Congregation of the most vulnerable
(i.e., those with CD4+ T-cell count <50cells/mm3)w i t h
those with unknown rates of multidrug or extensively drug
resistant TB has led to devastating consequences in South
African settings [32]. Hospitalization to overcome challenges
and logistical issues of TB/HIV treatments must therefore be
initiated with programmatic interventions that can reduce
risk.
“Knowyourstatus”campaignscombinedwithaggressive
community-basedTBcaseﬁndingcampaignswilloﬀerlong-
term solutions [4, 5]. The former will avoid discovery of
the HIV patient presenting late into care with a low CD4+
T-cell count. The later will reduce transmission risk for
all. Until those public health interventions can be broadly
implemented, the integrated TB/HIV clinical service must
look for solutions to translate clinical trials ﬁndings and
recommendations into best practice scenarios.
Perhaps the most notable strength of the Kericho inte-
grated TB/HIV clinic was the very early recognition of the
need for integrating services (one patient, one clinic) and the
institution of an integrated clinic into routine practice at a
Ministry of Health facility. The most important limitation
to recognize is the retrospective, uncontrolled nature of our
analyses and those limitations (e.g., missing data) and biases
(e.g., selection, referral, and report biases) inherent in all
suchsecondaryanalyses.Tothatend,analyseswereidentiﬁed
as exploratory and results are best considered hypotheses
supporting or generating. While particular caution should
be given to interpretations of pediatric data alone due to the
low proportion of pediatric patients, we feel that a strength
of the integrated TB/HIV clinic is the inclusion of pediatric
patients.
5. Conclusions
TB/HIV patients with advanced HIV disease can be suc-
cessfully managed in integrated TB/HIV MoH clinics in
rural Kenya. Treatment outcomes improve with time, likely
reﬂecting a variety of factors certainly including additional
expertisethatfollowsexperience.BaselineCD4+T-cellcount
is a driving force in predicting outcomes. Loss to followup
remains a critical challenge in care delivery that demands
attention and innovation. With high loss to followup occur-
ring early in care and likely representing further deaths,
the beneﬁts and challenges of early ART initiation in TB
treatment in nonclinical trial, resource-limited, rural set-
tings are underscored. This “TB/HIV timeline” conundrum
underscores the need for increased eﬀorts for early detection
of TB/HIV coinfected patients combined with innovative
caseholdinginterventions.AnintegratedTB/HIVclinic(one
patient, one clinic) is a feasible goal in resource-constrained
settings.
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